Close

BIO Comments at August Meeting of the National Advisory Council Subcommittee Identifying Quality Measures for Medicaid Eligible Adults

Aug 9 2011
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the core set of health quality measures for the Medicaid Quality Measurement Program created by the Affordable Care Act (ACA). BIO supports the development and use of appropriate, evidence-based quality measures throughout the healthcare system, and we feel that adult immunizations should be included in the Medicaid core quality measures. Creating comprehensive quality measures for adult immunizations will help ensure that healthcare providers routinely discuss and offer vaccines to their patients, resulting in higher vaccine uptake among adults, better health outcomes, and cost savings for the Medicaid program. BIO recommends that CMS, AHRQ, and the Subcommittee conduct a rigorous gap analysis to assess areas where ACIP recommendations exist but quality measures do not. New adult immunization quality measures should then be elevated to the highest priority for development, testing, and validation, as immunizations have a proven history of providing quality outcomes.

Comments of Biotechnology Industry Organization on DRAFT LCFS Sustainability Principles, Criteria, Indicators Principles 4, 5, 6, 7

Aug 5 2011
Comments on the DRAFT document by California Air Resources Board’s (CARB) Low Carbon Fuel Standard (LCFS) Sustainability Working Group on LCFS Sustainability Principles, Criteria, Indicators for Principles 4, 5, 6, and 7 (Draft Sustainability Principles).

Comments of Biotechnology Industry Organization on DRAFT LCFS Sustainability Principles, Criteria, Indicators Principles 4, 5, 6, 7

Aug 5 2011
Comments on the DRAFT document by California Air Resources Board’s (CARB) Low Carbon Fuel Standard (LCFS) Sustainability Working Group on LCFS Sustainability Principles, Criteria, Indicators for Principles 4, 5, 6, and 7 (Draft Sustainability Principles).

Animal Biotechnology: Letter in Support of a Science-Based Review Process at FDA

Aug 2 2011
In this letter to Congress, the members of the Animal Agriculture Coalition urge members not to disrupt funding for the FDA's review of genetically enhanced salmon.

Medicare Coverage Gap Discount Program: BIO’s Comments on CMS’s Memorandum on Proposed Changes to the Medicare Coverage Gap Discount Program – Low-Volume Claims and Clarifications

Aug 1 2011
The Biotechnology Industry Organization (BIO) appreciates this opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS) memorandum regarding proposed changes to the Medicare Coverage Gap Discount Program Agreement relating to low volume claims (Low-Volume Memorandum).

BIO Comments on a Prospective Standard to Mitigate the Risk of Occupational Exposure to Infectious Agents in Healthcare and Healthcare-related Settings

Jul 29 2011
  BIO fully supports the creation of an infectious disease standard by the Occupational Safety and Health Administration (OSHA) to protect healthcare workers (HCWs), and BIO believes that vaccinations should be an integral part of this standard. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) strongly recommends that HCWs receive vaccinations against the following diseases: hepatitis B, influenza, measles-mumps-rubella, varicella, and tetanus-diphtheria-pertussis. An OSHA standard that requires employers to make ACIP-recommended vaccines available to HCWs has the potential to impact worker safety significantly by increasing vaccination coverage.

Testimony in Support of USDA Research

Jul 28 2011
BIO submitted testimony in support of USDA research funding to the House Agriculture Subcommittee on Rural Development, Research, Biotechnology, and Foreign Agriculture. Ag research programs within the USDA have sparked agricultural innovation and will help to solve the critical food and energy security challenges facing a rapidly growing global population.

BIO Submits Comments on Financial Disclosure by Clinical Investigators Guidance

Jul 25 2011
BIO supports policies that emphasize disclosure of financial interests, rather than prohibiting certain relationships.

BIO Supports the Pandemic and All-Hazards Preparedness (PAHPA) Reauthorization Act of 2011

Jul 25 2011
In a letter to Representative Mike Rogers commending his support and introduction of H.R. 2405, BIO stresses the simultaneous reauthorization of Project BioShield and the Special Reserve Fund.

BIO Comments Following FDA Public Meeting: Ultra High Throughput Sequencing for Clinical Diagnostic Applications

Jul 23 2011
BIO commends the FDA for prospectively seeking input from industry to ensure that the regulatory environment is supportive of the rapid technological advancement of clinical diagnostic applications.